$ANIP (ANI Pharmaceuticals, Inc.)

$ANIP {{ '2016-06-13T13:27:51+0000' | timeago}} • Announcement

$ANIP said it got FDA approval of Prior Approval Supplement (PAS) for Oxcarbazepine Tablets, 150mg, 300mg and 600mg. Oxcarbazepine is antiepileptic drug indicated for use as monotherapy or adjunctive therapy in treatment of partial seizures in adults and as monotherapy in treatment of partial seizures in children aged 4 years & above with epilepsy.

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$ACET {{ '2018-01-02T20:11:33+0000' | timeago}} • Announcement

$ACET's finished dosage form generics subsidiary Rising Pharmaceuticals launched the first generic for Efavirenz Capsules. This is an FDA-approved generic version of the reference listed drug, Sustiva from $BMY, which in combination with other drugs is indicated for the treatment of HIV-1 infection in adults and pediatric patients.

$ANIP {{ '2017-12-29T17:23:26+0000' | timeago}} • Announcement

$ANIP acquired the NDAs and US rights to market ATACAND, ATACAND HCT, ARIMIDEX, and CASODEX from AstraZeneca for $46.5MM in cash, royalties, and sales-based milestones. AstraZeneca will continue to market and supply these four products outside the US. The acquisitions were funded through a combination of cash and debt.

$ANIP {{ '2017-12-29T17:17:28+0000' | timeago}} • Announcement

$ANIP has entered a new five-year Senior Secured Credit Facility for up to $125MM with Citizens Bank. The facility is comprised of a $75MM five-year term loan that was closed in support of $ANIP’s acquisition of four NDAs acquired from AstraZeneca for $46.5MM in cash. This facility also includes a $50MM Senior Secured Revolving Credit Facility.

$MYL {{ '2017-12-29T16:32:47+0000' | timeago}} • Announcement

$MYL announced the U.S.launch of Estradiol Vaginal Cream, the first generic version of Allergan's Estrace Cream. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated in the treatment of vulvar and vaginal atrophy.

$MYL {{ '2017-12-29T10:49:56+0000' | timeago}} • Announcement

$MYL said the biosimilar Trastuzumab, co-developed by the company and Biocon Ltd. has been approved by ANVISA, the Brazilian regulatory agency, through their partner Libbs Farmaceutica. Trastuzumab is indicated for the treatment of breast cancer and gastric cancer. Libbs will commercialize the product in Brazil under the brand name Zedora.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$LCI {{ '2017-12-21T16:48:17+0000' | timeago}} • Announcement

$LCI BoD named Timothy C. Crew as the company's chief executive officer, effective January 2, 2018. He has over 25 years of experience in the generic and branded pharmaceutical industries. Crew will succeed Arthur Bedrosian, the current CEO.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$ABBV {{ '2017-12-21T13:23:43+0000' | timeago}} • Announcement

$ABBV announced positive top-line results from the Phase 3 SELECT-MONOTHERAPY clinical trial. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.

$IPXL {{ '2017-12-19T14:14:39+0000' | timeago}} • Announcement

$IPXL agreed to sell its manufacturing facility in Taiwan to Bora Pharmaceuticals. Bora will buy all issued share capital in Impax Taiwan and certain loans outstanding between Impax and Impax Taiwan for $18.5MM. $IPXL expects to record pre-tax impairment charge of about $70-80MM in 4Q17. The deal will close in 1Q18.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$BMY {{ '2017-12-18T12:54:53+0000' | timeago}} • Announcement

$BMY announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the approval of Yervoy for pediatric patients 12 years of age and older who have unresectable or metastatic melanoma. The CHMP recommendation will now be reviewed by the European Commission.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

$ZTS {{ '2017-12-12T13:32:16+0000' | timeago}} • Announcement

$ZTS BoD declared 1Q18 dividend of $0.126 per share of the company’s common stock, an increase of 20% from the quarterly dividend rate paid in 2017. The dividend is to be paid on Thursday, March 1, 2018, to holders of record on Friday, January 19, 2018.

Recent Transcripts

BTX (BioTime, Inc.)
Thursday, November 9 2017 - 9:30pm
PBYI (Puma Biotechnology, Inc.)
Thursday, November 9 2017 - 9:30pm
IPXL (Impax Laboratories Inc.)
Thursday, November 9 2017 - 1:30pm
CBM (Cambrex Corporation.)
Tuesday, November 7 2017 - 1:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 7 2017 - 1:00pm
LCI (Lannett Company, Inc.)
Monday, November 6 2017 - 9:30pm
MYL (Mylan N.V.)
Monday, November 6 2017 - 3:30pm
ACET (Aceto Corp.)
Friday, November 3 2017 - 1:00pm
ANIP (ANI Pharmaceuticals, Inc.)
Thursday, November 2 2017 - 2:30pm
ZTS (Zoetis Inc.)
Thursday, November 2 2017 - 12:30pm
PBH (Prestige Brands Holdings, Inc.)
Thursday, November 2 2017 - 12:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
ABBV (AbbVie Inc.)
Friday, October 27 2017 - 1:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm
VAR (Varian Medical Systems, Inc.)
Wednesday, October 25 2017 - 9:00pm
GSK (GlaxoSmithKline plc)
Wednesday, October 25 2017 - 1:00pm
ACET (Aceto Corp.)
Friday, August 25 2017 - 1:00pm
LCI (Lannett Company, Inc.)
Wednesday, August 23 2017 - 8:30pm
AMS (American Shared Hospital Services)
Thursday, August 10 2017 - 7:00pm
MYL (Mylan N.V.)
Wednesday, August 9 2017 - 2:00pm

AlphaGraphics you may like